CRVS · Corvus Pharmaceuticals, Inc.
$13.03
-0.28 (-2.10%)
At close · Jul 29
Market Cap
$1.12B
Shares
84.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.31
Open$12.97
Day$12.53–13.35
52W$3.96–26.95
Avg vol 30d1.3M
Short int18.1M · 21.5% float · 12.6d
Short vol62%
Last earningsMay 14, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Very Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+3%
above
Price vs 50-day avg
+1%
above
RSI (14)
44
neutral
MACD trend
Negative
52-week position
41%
mid-range
Momentum
relative strength
1-month return
−8%
trailing
6-month return
−38%
trailing
YTD return
+73%
this year
Relative strength
−45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
25 of 164 funds reported for Jun 30 · net +46.0K sh shares · +5 new
Insider flow
Accumulating
Net +$333.7K over 90 days · 0% sells
Short interest
Falling
21.48% of float · ▼ -4.0% MoM · 12.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
164 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
EPS growth
+48%
Y/Y
Free cash flow
$-33.0M
Balance sheet
$4.6M
net cash
Quant / Vol
risk profile
Volatility
180%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+3%
Bullish
Price vs 50-day avg
+1%
Bullish
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
41%
Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
No cross
50d $13 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
25 of 164 funds reported for Jun 30 · net +46.0K sh shares · +5 new
Insider flow
Accumulating
Net +$333.7K over 90 days · 0% sells
Short interest
Falling
21.48% of float · ▼ -4.0% MoM · 12.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
164 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $13 · 41%
52-wk high $27
vs 200-day avg +3%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRVS
this stock
Corvus Pharmaceuticals, Inc.
|
$1.12B | +72.9% | — | — | 21.5% |
|
ONC
BeOne Medicines Ltd.
|
$474.96B | +8.8% | +22179.2% | 966.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRVS | -8.0% | -8.1% | -37.6% | -10.9% | +72.9% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -7.0% | -8.1% | -45.1% | -10.1% | +64.2% |
Key facts
CIK
1626971
CUSIP
221015100
13F (30d)
21 filings
21 filers
Visit website
Investor relations